Updates are available Correction dated 2022-04-25

Article History

Received: 13 September 2021

Accepted: 12 January 2022

First Online: 3 February 2022

Change Date: 25 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10792-022-02249-x

Declarations

:

: EB: None. MTH: Allergan / Abbvie: Consultant/Advisor, Lecture Fees; Eyelight: Consultant/Advisor; ELT Sight: Consultant/Advisor; Glaukos Corporation: Lecture Fees; Heidelberg Engineering: Lecture Fees; IRIDEX: Consultant/Advisor, Lecture Fees, Travel Reimbursement, Research Grant; MLase AG: Consultant/Advisor, Lecture Fees; Novartis, Alcon Pharmaceuticals: Lecture Fees; Reichert: Consultant/Advisor, Lecture Fees; Santen, Inc.: Consultant/Advisor, Lecture Fees, Research Grant; Théa Pharma: Lecture Fees. MTH is a consultant for Iridex. In addition, he received lecture fees and travel reimbursement from Iridex.

: The study was approved by the local ethics committee (cantonal ethics committee of the canton of Zurich, registration ID 2020–00,219).

: Patients who decided not to participate in research (negative general consent) were excluded. Consent for publication. Data from patients with a valid signed general consent were included. In cases, a general consent or a negative general consent was not available, an informed consent was obtained. Not applicable.